Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients

Medical Science Monitor

Volumn 17, Issue 3, 2011, Pages 17-

  Feola, Mauro ^a   Lombardo, Enrico ^a   Taglieri, Camillo ^a   Vallauri, Paola ^a   Piccolo, Salvatore ^a   Valle, Roberto ^b  

^a Cardiovascular Rehabilitation Heart Failure Unit Ospedale SS Trinita'   (Italy)

^b Cardiology Division Ospedale Chioggia   (Italy)

Author keywords

Brain natriuretic peptide; End stage heart failure; Levosimendan

Indexed keywords

BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CREATININE; ENALAPRIL; FUROSEMIDE; LEVOSIMENDAN; SPIRONOLACTONE;

AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; ECHOCARDIOGRAPHY; EXERCISE TEST; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; MALE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 79952393231     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881433     Document Type: Article

References (34)

1. McBride B, White M: Levosimendan: implications for clinicians. J Clin Pharmacol, 2003; 43: 1071-81
2. Haikala H, Kaivola J, Nissinen E et al: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol, 1995; 27: 1859-66
3. Pollesello P, Ovaska M, Kaivola J et al: Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescent probe and proton nuclear magnetic resonance study. J Biol Chem, 1994; 269: 25584-90
4. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocites. Eur J Pharmacol, 1997; 333: 249-59
5. Kersten JR, Montgomery MW, Pagel PS, Warltier DC: Levosimendan, a new positive inotropic drug, decrease infarct size via activation (ATP) channels. Anesth Analg, 2000; 90: 5-11
6. Nieminen MS, Akkila J, Hasenfuss G et al: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol, 2000; 36: 1903-12
7. Moiseyev VS, Poder P, Andrejevs N et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized placebo-controlled, double-blind trial. Eur Heart J, 2002; 23: 1422-32
8. Follath F, Cleland JGF, Just H et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet, 2002; 360: 196-202
9. Lehmann A, Lang J, Boldt J et al: Levosimendan in patients with cardiogenic shock undergoing surgical revscularization: a cese series. Med Sci Monit, 2004; 10(8): MT89-93
10. Mebazaa A, Nieminen MS, Packer M et al: M. Levosimendan vs dobutamine for patients with acute decompensate heart failure: the SURVIVE Randomized trail. JAMA, 2007; 297: 1883-91
11. Spargias KS, Aniftantakis A, Papadakis M et al: Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure. Ital Heart J, 2003; (Suppl.2): 45S-49S
12. Nanas JN, Papazoglou P, Ntalianis A et al: Efficacy and safety of intermittent, long-term, concomitant dobuatmine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol, 2005; 95: 768-71
13. Parissis JT, Adamoupoulos S, Farmakis D et al: Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart, 2006; 92(12): 1768-72
14. Mavrogeni S, Giamouzis G, Papadopoulou E et al: A 6-month followup of intermittent levosimendan administration effect on systolic function, specific activity questionnaire and arrhythmia in advanced heart failure. J Cardiac Fail, 2007; 13: 556-59
15. Mckee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of CHF. The Framingham study. N Engl J Med, 1971; 285: 1442-46
16. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J, 2008; 29: 2388-42
17. Rector TS, Kubo SH, Cohn JN: Patients' self-assessment of their congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure, 1987; 198-209
18. Sahn DJ, Demaria A, Kisslo J, Weyman A: The committee on M mode standardisation of the American Society of Echocardiography: recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation, 1978; 58: 1072-83
19. Garcia MJ, Thomas JD, Klein AL: New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol, 1998; 32: 865-75
20. Gottdiener JS, Bednarz J, Devereux R: American Society of Echocardiography. American Society of Echocardiography Recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr, 2004; 17: 1086-119
21. Lindquist P, Calcutteea A, Henein M: Echocardiography in the assessment of right heart function. Eur J Echocardiogr, 2008; 9: 225-34
22. Agostoni PG, Cattadori G, Apostolo A et al: Non-invasive measurement of cardiac output during exercise by inert gas rebreathing technique: a New tool for heart failure evolution. J Am Coll Cardiol, 2005; 46: 1779-83
23. Rapezzi C, Bracchetti G, Branzi A, Magnani B: The case against outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant, 2000; 19(Suppl.): S58-S63
24. Garin O, Ferrer M, Pont A et al: Disease- specific health-related quality of life questionnaires for heart failure: a systematic review with meta- analyses. Qual Life Res, 2009: 18: 71-85
25. Farmakis D, Parissis JT, Bistola V et al: Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. Int J Cardiol, 2010; 139: 75-79
26. Lilleberg J, Laine M, Palkama T et al: Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail, 2007; 9: 75-82
27. Parissis JT, Andreadou I, Bistola V et al: Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs, 2008; 17: 1143-50
28. Nanas S, Gerovasili V, Dimopoulos S et al: Inotropic agents improve the peripheral microcirculation of patients with end-stage chronic heart failure. J Card Fail, 2008; 14: 400-6
29. Ochala J: Ca2+sensitizers: an emerging class of agents for counterbalancing weakness in skeletal muscle diseases? Neuromuscul Disord, 2010; 20: 98-101
30. Altenberger J, Parissis JT, Ulmer H, Poelzl G: Rationale and design of the multicenter randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study). Eur J Heart Fail, 2010; 12: 186-92
31. Feola M, Aspromonte N, Canali C et al: Prognostic value of plasma brain natriuretic peptide, Urea nitrogen and creatinine in outpatients >70 years of age with heart failure. Am J Cardiol, 2005; 96(5): 705-9
32. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B: Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Cardiac Fail, 2007; 13: 417-21
33. Pagel P, Hettrick D, Warltier D: Influence of levosimendan, pimobendan and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol, 1996; 119: 609-15
34. Parle NM, Thomas MD, Dembo L, Driscoll GO: Repeated infusions of levosimendan. Well tolerated and improves functional capacity in decompensated heart failure-a single-centre experience. Heart, Lung and Circulation, 2008; 3: 206-10